Spero Therapeutics (NASDAQ:SPRO) plans to initiate a Phase II trial of its lead immunology candidate, SP001, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results